UK-based pharmaceutical company AstraZeneca has seen its market value overtake its US rival Pfizer’s, just days before the company releases its quarterly earnings.   AstraZeneca is now topping the London Stock Exchange with a market value of £189 billion – a rise of 19.60% since the same time last year.   On the New York Stock Exchange, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!